Biomarin Pharmaceutical Inc
(NAS:BMRN)
$
66.19
0.06 (0.09%)
Market Cap: 12.61 Bil
Enterprise Value: 12.28 Bil
PE Ratio: 39.63
PB Ratio: 2.33
GF Score: 67/100 Biomarin Pharmaceutical Inc at Goldman Sachs Healthcare CEOs Unscripted: A View from the Top Transcript
Jan 09, 2020 / 01:45PM GMT
Release Date Price:
$89.58
(+5.75%)
Salveen Jaswal Richter
Goldman Sachs Group Inc., Research Division - VP
Great. Well, good morning, everyone. Thanks for joining us. I'm Salveen Richter. I cover the biotechnology sector at Goldman Sachs. It's a good day to have the Chairman and CEO of BioMarin with us, Jean-Jacques Bienaimé.
Questions & Answers
Salveen Jaswal Richter
Goldman Sachs Group Inc., Research Division - VP
And with that, J.J., maybe starting the first question. As we enter the new decade, looking back, how has BioMarin evolved as a company? What can we really expect here over the next 10 years?
Jean;Jacques BienaimÃ;BioMarin Pharmaceutical Inc.;Chairman;CEO
©,-&
So good morning, everyone. It's pleasure to be here. Thank you, Salveen, for having us.
[With this], we've known each other for quite a while. I think you've been following BioMarin almost since I joined the company or a couple of years later. So I joined the company 14.5 years ago. So if you look back,
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot